JP2010505432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010505432A5 JP2010505432A5 JP2009531824A JP2009531824A JP2010505432A5 JP 2010505432 A5 JP2010505432 A5 JP 2010505432A5 JP 2009531824 A JP2009531824 A JP 2009531824A JP 2009531824 A JP2009531824 A JP 2009531824A JP 2010505432 A5 JP2010505432 A5 JP 2010505432A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligomer
- oligomer according
- lna
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 29
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 15
- 239000002773 nucleotide Substances 0.000 claims 14
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 108020004414 DNA Proteins 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 230000000295 complement effect Effects 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102100034343 Integrase Human genes 0.000 claims 3
- 101710203526 Integrase Proteins 0.000 claims 3
- 229910019142 PO4 Inorganic materials 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 102000053786 human PCSK9 Human genes 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- RHCSKNNOAZULRK-APZFVMQVSA-N 2,2-dideuterio-2-(3,4,5-trimethoxyphenyl)ethanamine Chemical compound NCC([2H])([2H])C1=CC(OC)=C(OC)C(OC)=C1 RHCSKNNOAZULRK-APZFVMQVSA-N 0.000 claims 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 claims 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims 1
- HBJGQJWNMZDFKL-UHFFFAOYSA-N 2-chloro-7h-purin-6-amine Chemical compound NC1=NC(Cl)=NC2=C1NC=N2 HBJGQJWNMZDFKL-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 claims 1
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical compound NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 229930024421 Adenine Natural products 0.000 claims 1
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 claims 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 1
- 229930010555 Inosine Natural products 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 229960003786 inosine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- -1 nucleic acid salts Chemical class 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82873506P | 2006-10-09 | 2006-10-09 | |
| US97293207P | 2007-09-17 | 2007-09-17 | |
| US97740907P | 2007-10-04 | 2007-10-04 | |
| PCT/EP2007/060703 WO2008043753A2 (en) | 2006-10-09 | 2007-10-09 | Rna antagonist compounds for the modulation of pcsk9 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010505432A JP2010505432A (ja) | 2010-02-25 |
| JP2010505432A5 true JP2010505432A5 (https=) | 2010-12-02 |
Family
ID=39125211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009531824A Withdrawn JP2010505432A (ja) | 2006-10-09 | 2007-10-09 | Ｐｃｓｋ９を調節するためのｒｎａアンタゴニスト化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100216864A1 (https=) |
| EP (2) | EP2076597A2 (https=) |
| JP (1) | JP2010505432A (https=) |
| AU (1) | AU2007306361A1 (https=) |
| CA (1) | CA2666191C (https=) |
| ES (1) | ES2603379T3 (https=) |
| IL (1) | IL197668A0 (https=) |
| MX (1) | MX2009003729A (https=) |
| WO (1) | WO2008043753A2 (https=) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009536222A (ja) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｐｃｓｋ９の発現を調節するための化合物および方法 |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| CA2670563A1 (en) | 2006-11-27 | 2008-06-05 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| US8470791B2 (en) | 2007-03-22 | 2013-06-25 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
| JP2010537958A (ja) * | 2007-08-30 | 2010-12-09 | サンタリス ファーマ アー／エス | Ｆａｂｐ４／ａｐ２を調節するためのｒｎａアンタゴニスト化合物 |
| US20110224280A1 (en) * | 2008-04-16 | 2011-09-15 | Niels Fisker Nielsen | Pharmaceutical Composition Comprising Anti PCSK9 Oligomers |
| WO2009143367A2 (en) * | 2008-05-22 | 2009-11-26 | Schering Corporation | Egf-a domain-mediated modulation of pcsk9 |
| WO2009148605A2 (en) * | 2008-06-04 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| EP2456870A1 (en) * | 2009-07-21 | 2012-05-30 | Santaris Pharma A/S | Antisense oligomers targeting pcsk9 |
| EP2490699A1 (en) | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
| GB2481373A (en) * | 2010-06-21 | 2011-12-28 | Weiming Xu | Treatment of hypercholesterolaemia by ubiquitination of PCSK9 |
| US9127280B2 (en) | 2010-08-31 | 2015-09-08 | Osaka University | Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient |
| CA2817256A1 (en) | 2010-11-12 | 2012-05-18 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| CA2817960C (en) | 2010-11-17 | 2020-06-09 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| AU2012205718B2 (en) | 2011-01-10 | 2017-07-06 | The Regents Of The University Of Michigan | Stem cell factor inhibitor |
| US20150018408A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
| WO2013001372A2 (en) | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
| EA029234B1 (ru) | 2011-07-06 | 2018-02-28 | Сюкехусет Сёрланнет Хф | Нацеленная на egfr терапия |
| AU2012308320C1 (en) | 2011-09-14 | 2018-08-23 | Translate Bio Ma, Inc. | Multimeric oligonucleotide compounds |
| JP6112569B2 (ja) | 2011-12-16 | 2017-04-12 | 国立大学法人 東京医科歯科大学 | キメラ２重鎖核酸 |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| WO2013173652A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
| JP2015165772A (ja) * | 2012-07-04 | 2015-09-24 | 国立大学法人大阪大学 | オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する脂質異常症治療剤 |
| CN104968783B (zh) | 2012-10-15 | 2019-12-10 | Ionis制药公司 | 用于调节c9orf72表达的组合物 |
| EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHOD FOR MONITORING THE C9ORF72 EXPRESSION |
| ES2762326T5 (es) | 2012-10-15 | 2023-04-27 | Ionis Pharmaceuticals Inc | Métodos para modular la expresión de C9ORF72 |
| US10058630B2 (en) | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| CN104837996A (zh) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | 抗apob反义缀合物化合物 |
| CA2891855A1 (en) | 2012-12-21 | 2014-06-26 | Sykehuset Sorlandet Hf | Egfr targeted therapy of neurological disorders and pain |
| AU2014211406B2 (en) | 2013-01-30 | 2019-07-18 | Roche Innovation Center Copenhagen A/S | LNA oligonucleotide carbohydrate conjugates |
| WO2014132671A1 (en) | 2013-03-01 | 2014-09-04 | National University Corporation Tokyo Medical And Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
| EP3004347B1 (en) | 2013-05-30 | 2018-09-26 | National University Corporation Tokyo Medical and Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
| AU2014282666A1 (en) | 2013-06-16 | 2016-01-07 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
| HUE048738T2 (hu) | 2013-06-27 | 2020-08-28 | Roche Innovation Ct Copenhagen As | Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg |
| US10221414B2 (en) * | 2013-10-11 | 2019-03-05 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C9ORF72 expression |
| EP3161159B1 (en) | 2014-06-25 | 2020-08-05 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| EP3271405A1 (en) * | 2015-03-20 | 2018-01-24 | Aarhus Universitet | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders |
| US20180140747A1 (en) * | 2015-04-15 | 2018-05-24 | ConcieValve LLC | Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis |
| RS60230B1 (sr) | 2015-04-16 | 2020-06-30 | Ionis Pharmaceuticals Inc | Kompozicije za moduliranje ekspresije c9orf72 |
| WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
| EP3418289B1 (en) | 2016-02-17 | 2026-04-08 | Institute Of Science Tokyo | Artificial nucleoside and artificial nucleotide, and artificial oligonucleotide |
| EP3517610A4 (en) | 2016-09-23 | 2020-05-27 | National University Corporation Tokyo Medical and Dental University | THROUGH HETERODUPLEX NUCLEIC ACID THROUGH BLOOD BRAIN CABINET |
| US11260134B2 (en) | 2016-09-29 | 2022-03-01 | National University Corporation Tokyo Medical And Dental University | Double-stranded nucleic acid complex having overhang |
| AU2018215440B2 (en) | 2017-02-06 | 2024-10-24 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| US11273222B2 (en) | 2017-05-26 | 2022-03-15 | National Cerebral And Cardiovascular Center | Antisense nucleic acid targeting PCSK9 |
| EP3647423A4 (en) | 2017-06-30 | 2021-03-24 | National University Corporation Tokyo Medical and Dental University | DOUBLE STRANDED HETERO-ANTI-MIRNA |
| BR112020001430A2 (pt) | 2017-07-26 | 2020-07-28 | Nissan Chemical Corporation | oligonucleotídeo de fita simples |
| EP3760209B1 (en) | 2018-02-28 | 2023-11-22 | National University Corporation Tokyo Medical and Dental University | Ischemic-lesion-site-specific gene therapy |
| JP7394392B2 (ja) | 2018-03-14 | 2023-12-08 | 国立大学法人 東京医科歯科大学 | 核酸複合体 |
| EP3769769A4 (en) | 2018-03-19 | 2022-05-04 | National University Corporation Tokyo Medical and Dental University | NUCLEIC ACID WITH REDUCED TOXICITY |
| BR112020018902A2 (pt) | 2018-03-20 | 2021-01-26 | Tokyo Institute Of Technology | oligonucleotídeo antissenso com toxicidade reduzida |
| JP7262816B2 (ja) | 2018-03-22 | 2023-04-24 | 国立大学法人 東京医科歯科大学 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
| WO2020022499A1 (ja) | 2018-07-27 | 2020-01-30 | 国立大学法人大阪大学 | 老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物 |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12492399B2 (en) | 2019-03-14 | 2025-12-09 | Rena Therapeutics Inc. | Nucleic acid complex for regulating IHH expression |
| CN113677374A (zh) | 2019-04-08 | 2021-11-19 | 国立大学法人东京医科齿科大学 | 肌疾病治疗用药物组合物 |
| WO2021054370A1 (ja) | 2019-09-18 | 2021-03-25 | 国立大学法人東京医科歯科大学 | 核酸複合体 |
| EP4043565A4 (en) | 2019-10-11 | 2024-01-24 | National University Corporation Tokyo Medical and Dental University | MODIFIED HETERONUCLEIC ACID |
| KR20220133925A (ko) | 2020-01-31 | 2022-10-05 | 가부시키가이샤산와카가쿠켄큐쇼 | Atn1의 안티센스 올리고뉴클레오티드 |
| EP4116419A1 (en) | 2020-03-04 | 2023-01-11 | Nissan Chemical Corporation | Antisense oligonucleotide of calm2 |
| EP4123023A4 (en) | 2020-03-16 | 2024-07-17 | National University Corporation Tokyo Medical and Dental University | Heteronucleic acid containing morpholino nucleic acid |
| CA3202832A1 (en) | 2020-12-31 | 2022-07-07 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP4349986A4 (en) | 2021-05-25 | 2025-11-19 | Univ Nat Corp Tokyo Medical & Dental | HETERONUCLEIC ACID WITH A CONTENT OF ?????? OR ???? |
| AU2022285344A1 (en) | 2021-05-31 | 2023-12-14 | Rena Therapeutics Inc. | Ligand-bound nucleic acid complex |
| JPWO2023022229A1 (https=) | 2021-08-19 | 2023-02-23 | ||
| US20240390508A1 (en) | 2021-08-21 | 2024-11-28 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| EP4403191A4 (en) | 2021-09-15 | 2026-03-18 | Univ Nat Corp Tokyo Medical & Dental | HETERONUCLEIC ACID COMPRISING A 2'-MODIFIED NUCLEOSIDE |
| EP4428238A1 (en) | 2021-11-02 | 2024-09-11 | Rena Therapeutics Inc. | Ligand-bound nucleic acid complex |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| EP4596694A1 (en) | 2022-09-29 | 2025-08-06 | Institute Of Science Tokyo | Nucleic acid molecule containing 5'-cyclopropylene modification |
| EP4612184A1 (en) | 2022-11-04 | 2025-09-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| KR20250116795A (ko) | 2022-11-14 | 2025-08-01 | 리제너론 파마슈티칼스 인코포레이티드 | 별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법 |
| WO2025047953A1 (ja) | 2023-08-30 | 2025-03-06 | 株式会社Stratoimmune | ＲａｓＧＲＰ４のアンチセンスオリゴヌクレオチド |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3719766A1 (de) * | 1987-06-13 | 1988-12-22 | Heidelberger Druckmasch Ag | Registermesssystem |
| US4914210A (en) * | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| WO1994005813A1 (en) * | 1992-09-10 | 1994-03-17 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Compositions and methods for treatment of hepatitis c virus-associated diseases |
| US6423489B1 (en) * | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US6433159B1 (en) * | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
| DK0832069T3 (da) * | 1995-06-07 | 2003-04-22 | Pfizer | Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) |
| EA001539B1 (ru) * | 1996-11-27 | 2001-04-23 | Пфайзер Инк. | Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр) |
| CA2283379A1 (en) * | 1997-03-05 | 1998-09-11 | Michael G. Katze | Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication |
| US6410323B1 (en) * | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US7029895B2 (en) * | 1999-09-27 | 2006-04-18 | Millennium Pharmaceuticals, Inc. | 27411, a novel human PGP synthase |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| EP1257572A2 (en) | 2000-02-07 | 2002-11-20 | Millennium Pharmaceuticals, Inc. | Narc-1, subtilase-like homologs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| AU2003225495B2 (en) * | 2002-04-05 | 2009-01-15 | Roche Innovation Center Copenhagen A/S | Oligomeric compounds for the modulation HIF-1alpha expression |
| WO2003097662A1 (en) | 2002-05-15 | 2003-11-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein b expression |
| AU2003264038A1 (en) * | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Combination pharmaceutical agents as inhibitors of hcv replication |
| US7087229B2 (en) * | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| EP2336318B1 (en) | 2002-11-13 | 2013-04-24 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
| WO2004046160A2 (en) * | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
| FR2848572B1 (fr) * | 2002-12-12 | 2005-12-09 | Univ Joseph Fourier | Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices |
| EP1471152A1 (en) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
| US7683036B2 (en) * | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| WO2005073378A1 (en) | 2004-01-30 | 2005-08-11 | Santaris Pharma A/S | MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA) |
| ES2401114T3 (es) * | 2004-08-10 | 2013-04-17 | Genzyme Corporation | Modulación antisentido de la expresión de apolipoproteína B |
| US20060185027A1 (en) * | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| CA2658183A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
-
2007
- 2007-10-09 CA CA2666191A patent/CA2666191C/en active Active
- 2007-10-09 EP EP07821072A patent/EP2076597A2/en not_active Withdrawn
- 2007-10-09 US US12/444,806 patent/US20100216864A1/en not_active Abandoned
- 2007-10-09 AU AU2007306361A patent/AU2007306361A1/en not_active Abandoned
- 2007-10-09 EP EP11181596.5A patent/EP2444494B1/en active Active
- 2007-10-09 WO PCT/EP2007/060703 patent/WO2008043753A2/en not_active Ceased
- 2007-10-09 ES ES11181596.5T patent/ES2603379T3/es active Active
- 2007-10-09 JP JP2009531824A patent/JP2010505432A/ja not_active Withdrawn
- 2007-10-09 MX MX2009003729A patent/MX2009003729A/es not_active Application Discontinuation
-
2009
- 2009-03-18 IL IL197668A patent/IL197668A0/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505432A5 (https=) | ||
| US12303525B2 (en) | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection | |
| JP2009508527A5 (https=) | ||
| US20210024934A1 (en) | Use of fubp1 inhibitors for treating hepatitis b virus infection | |
| JP2016513976A5 (https=) | ||
| JP2009532044A5 (https=) | ||
| JP2025039668A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| JP2010537958A5 (https=) | ||
| US20190345496A1 (en) | Antisense oligonucleotides for modulating relb expression | |
| US20240294915A1 (en) | Oligonucleotides for Modulating Apolipoprotein E4 Expression | |
| JP7813254B2 (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| US20200216845A1 (en) | Antisense oligonucleotides for modulating rela expression | |
| US20190367920A1 (en) | Antisense oligonucleotides for modulating nfkb1 expression | |
| JP2024505583A (ja) | Ｒｔｅｌ１発現を阻害するための増強されたオリゴヌクレオチド | |
| JP2026074094A (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| HK40109677A (zh) | 用於调节载脂蛋白e4表达的寡核苷酸 | |
| HK40033074A (en) | Nucleic acid molecule for reduction of papd5 and papd7 mrna for treating hepatitis b infection |